{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T02:18:21Z","timestamp":1713406701481},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,17]]},"DOI":"10.7759\/cureus.58451","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:43:33Z","timestamp":1713354213000},"source":"Crossref","is-referenced-by-count":0,"title":["Co-occurrence of High-Risk Myelodysplastic Syndrome With a Complex Karyotype\/TP53 Mutation and IgG Lambda Monoclonal Gammopathy of Undetermined Significance"],"prefix":"10.7759","author":[{"given":"Marwa","family":"Mir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wajeeha","family":"Aiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Baah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunwant","family":"Guron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber DA","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al.. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022, 140:1200-28. 10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al.. The 5th edition of the World Health Organization classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022, 36:1703-19. 10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)70001-8","article-title":"Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study","volume":"1","author":"Kyle RA","year":"2014","unstructured":"Kyle RA, Larson DR, Therneau TM, et al.. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol. 2014, 1:e28-36. 10.1016\/S2352-3026(14)70001-8","journal-title":"Lancet Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:e538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.014","article-title":"Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition","volume":"87","author":"Therneau TM","year":"2012","unstructured":"Therneau TM, Kyle RA, Melton LJ 3rd, et al.. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc. 2012, 87:1071-9. 10.1016\/j.mayocp.2012.06.014","journal-title":"Mayo Clin Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long TE","year":"2022","unstructured":"Long TE, Indridason OS, Palsson R, et al.. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022, 12:133. 10.1038\/s41408-022-00732-3","journal-title":"Blood Cancer J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle RA","year":"2010","unstructured":"Kyle RA, Durie BG, Rajkumar SV, et al.. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010, 24:1121-7. 10.1038\/leu.2010.60","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61090-2","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan","volume":"82","author":"Iwanaga M","year":"2007","unstructured":"Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc. 2007, 82:1474-9. 10.1016\/S0025-6196(11)61090-2","journal-title":"Mayo Clin Proc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12827","article-title":"Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects","volume":"98","author":"Nolte F","year":"2017","unstructured":"Nolte F, Mossner M, Jann JC, et al.. Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects. Eur J Haematol. 2017, 98:302-10. 10.1111\/ejh.12827","journal-title":"Eur J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61901-7","article-title":"Myelodysplastic syndromes","volume":"383","author":"Ad\u00e8s L","year":"2014","unstructured":"Ad\u00e8s L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014, 383:2239-52. 10.1016\/S0140-6736(13)61901-7","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution","volume":"89","author":"Tang G","year":"2014","unstructured":"Tang G, Zhang L, Fu B, et al.. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol. 2014, 89:813-8. 10.1002\/ajh.23751","journal-title":"Am J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151858","article-title":"Co-occurrence of MDS with MGUS represents a unique disease entity with specific molecular phenotype and potential improved clinical outcome","volume":"138","author":"Kewan T","year":"2021","unstructured":"Kewan T, Ahmed R, Gurnari C, et al.. Co-occurrence of MDS with MGUS represents a unique disease entity with specific molecular phenotype and potential improved clinical outcome. Blood. 2021, 138:1529. 10.1182\/blood-2021-151858","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.01.003","article-title":"Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome","volume":"35","author":"Mallo M","year":"2011","unstructured":"Mallo M, Lu\u00f1o E, Sanzo C, et al.. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leuk Res. 2011, 35:834-6. 10.1016\/j.leukres.2011.01.003","journal-title":"Leuk Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen AJ","year":"2020","unstructured":"Menssen AJ, Walter MJ. Genetics of progression from MDS to secondary leukemia. Blood. 2020, 136:50-60. 10.1182\/blood.2019000942","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2019.389","article-title":"Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility.","volume":"10","author":"Shahjahani M","year":"2019","unstructured":"Shahjahani M, Hadad EH, Azizidoost S, et al.. Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility.. Oncology reviews vol. 13,1 389. 4 Feb. 2019, 10:4081. 10.4081\/oncol.2019.389","journal-title":"Oncology reviews vol. 13,1 389. 4 Feb"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0267-4","article-title":"Complex karyotype in myelodysplastic syndromes: diagnostic procedure and prognostic susceptibility","volume":"13","author":"Chen J","year":"2019","unstructured":"Chen J, Kao YR, Sun D, et al.. Complex karyotype in myelodysplastic syndromes: diagnostic procedure and prognostic susceptibility. Oncol Rev. 2019, 13:103-10. 10.1038\/s41591-018-0267-4","journal-title":"Oncol Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-3210","article-title":"Coexistence of plasma cell neoplasia and myelodysplastic syndrome with excess blasts: case reports and literature review","volume":"10","author":"Yan W","year":"2021","unstructured":"Yan W, Qu XY, Li H, et al.. Coexistence of plasma cell neoplasia and myelodysplastic syndrome with excess blasts: case reports and literature review. Ann Palliat Med. 2021, 10:12431-40. 10.21037\/apm-21-3210","journal-title":"Ann Palliat Med"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 mutation and its prognostic significance in Waldenstrom's macroglobulinemia","volume":"23","author":"Poulain S","year":"2017","unstructured":"Poulain S, Roumier C, Bertrand J, et al.. TP53 mutation and its prognostic significance in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2017, 23:6325-35.","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0196-9","article-title":"Regulating tumor suppressor genes: post-translational modifications","volume":"5","author":"Chen L","year":"2020","unstructured":"Chen L, Liu S, Tao Y. Regulating tumor suppressor genes: post-translational modifications. Signal Transduct Target Ther. 2020, 5:90. 10.1038\/s41392-020-0196-9","journal-title":"Signal Transduct Target Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12261","article-title":"The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma","volume":"93","author":"Khong T","year":"2008","unstructured":"Khong T, Sharkey J, Spencer A. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica. 2008, 93:860-9. 10.3324\/haematol.12261","journal-title":"Haematologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/245555-co-occurrence-of-high-risk-myelodysplastic-syndrome-with-a-complex-karyotypetp53-mutation-and-igg-lambda-monoclonal-gammopathy-of-undetermined-significance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:43:36Z","timestamp":1713354216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/245555-co-occurrence-of-high-risk-myelodysplastic-syndrome-with-a-complex-karyotypetp53-mutation-and-igg-lambda-monoclonal-gammopathy-of-undetermined-significance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.58451","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,17]]}}}